Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Non Operating Income: 2014-2025

Historic Non Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $7.8 million.

  • Viking Therapeutics' Non Operating Income fell 33.08% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 7.56%. This contributed to the annual value of $41.0 million for FY2024, which is 174.30% up from last year.
  • Viking Therapeutics' Non Operating Income amounted to $7.8 million in Q3 2025, which was down 13.75% from $9.0 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Non Operating Income ranged from a high of $11.8 million in Q2 2024 and a low of $142,000 during Q1 2022.
  • Its 3-year average for Non Operating Income is $7.5 million, with a median of $7.8 million in 2025.
  • As far as peak fluctuations go, Viking Therapeutics' Non Operating Income tumbled by 84.53% in 2021, and later surged by 2,168.84% in 2023.
  • Viking Therapeutics' Non Operating Income (Quarterly) stood at $154,000 in 2021, then soared by 370.13% to $724,000 in 2022, then spiked by 546.41% to $4.7 million in 2023, then surged by 131.22% to $10.8 million in 2024, then tumbled by 33.08% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $9.0 million for Q2 2025, and $9.8 million during Q1 2025.